Pharmacological management of fibromyalgia: a Bayesian network meta-analysis

References

• Lian YN, Wang Y, Zhang Y, et al. Duloxetine for pain in fibromyalgia in adults: a systematic review and a meta-analysis. Int J Neurosci. 2020;130(1):71–82.
   Google Scholar
• Bellato E, Marini E, Castoldi F, et al. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat. 2012;2012:426130.
   Google Scholar
• Bazzichi L, Giacomelli C, Consensi A, et al. One year in review 2020: fibromyalgia. Clin Exp Rheumatol. 2020;38(1):3–8. Suppl 123.
   Google Scholar
• Gracely RH, Petzke F, Wolf JM, et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46(5):1333–1343.
   Google Scholar
• Cook DB, Lange G, Ciccone DS, et al. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004;31(2):364–378.
   Google Scholar
• Bair MJ, Krebs EE. Fibromyalgia. Ann Intern Med. 2020;172(5):ITC33–ITC48.
   Google Scholar
• Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–328.
   Google Scholar
• Chen X, Zou K, Abdullah N, et al. The placebo effect and its determinants in fibromyalgia: meta-analysis of randomised controlled trials. Clin Rheumatol. 2017;36(7):1623–1630.
   Google Scholar
• Bernardy K, Klose P, Busch AJ, et al. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013;9:CD009796. DOI:https://doi.org/10.1002/14651858.CD009796.pub2
   Google Scholar
• Busch AJ, Barber KA, Overend TJ, et al. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev. 2007;4:CD003786. DOI:https://doi.org/10.1002/14651858.CD003786.pub2
   Google Scholar
• Kia S, Choy E. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines. 2017;5(2):20.
   Google Scholar
• Acet G, Kaya A, Akturk S, et al. A comparison of the effectiveness of amitriptilin and pregabalin treatment in fibromyalgia patients. North Clin Istanb. 2017;4(2):151–159.
   Google Scholar
• Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37(1):32–40.
   Google Scholar
• Gilron I, Chaparro LE, Tu D, et al. Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. Pain. 2016;157(7):1532–1540.
   Google Scholar
• Ware MA, Fitzcharles MA, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604–610.
   Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   Google Scholar
• CI HJ, Glasziou P, Greenhalgh T, et al. The 2011 Oxford CEBM levels of evidence. Oxford Centre for Evidence-Based Medicine Available at https://wwwcebmnet/indexaspx?o=5653. Accessed in Dec 2020
   Google Scholar
• Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18(5):728–733.
   Google Scholar
• Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160–164.
   Google Scholar
• Argoff CE, Emir B, Whalen E, et al. Pregabalin improves pain scores in patients with fibromyalgia irrespective of comorbid osteoarthritis. Pain Med. 2016;17(11):2100–2108.
   Google Scholar
• Bateman L, Palmer P, Trugman T, et al. Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. J Pain Res. 2013;6:311–318.
   Google Scholar
• Bennett R, Russell IJ, Choy E, et al. Evaluation of patient-rated stiffness associated with fibromyalgia: a post-hoc analysis of 4 pooled, randomized clinical trials of duloxetine. Clin Ther. 2012;34(4):824–837.
   Google Scholar
• Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, et al. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru. 2019;27(1):149–158.
   Google Scholar
• Braz AS, Morais LC, Paula AP, et al. Effects of Panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial. Braz J Psychiatry. 2013;35(1):21–28.
   Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264–1273.
   Google Scholar
• Fors EA, Sexton H, Gotestam KG. The effect of guided imagery and amitriptyline on daily fibromyalgia pain: a prospective, randomized, controlled trial. J Psychiatr Res. 2002;36(3):179–187.
   Google Scholar
• Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29(11):1371–1377.
   Google Scholar
• Hadianfard MJ, Hosseinzadeh Parizi M. A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine. Iran Red Crescent Med J. 2012;14(10):311–340.
   Google Scholar
• Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37(12):1279–1286.
   Google Scholar
• Zhang X, Xu H, Zhang Z, et al. Effcacy and safety of pregabalin for fibromyalgia in a population of Chinese patients: a phase 3, randomized, double-blind, placebo- controlled trial. Arthritis Rheumatol. 2017;69:NR.
   Google Scholar
• Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112(3):191–197.
   Google Scholar
• Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974–2984.
   Google Scholar
• Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1–3):5–15.
   Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9):792–805.
   Google Scholar
• Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clin J Pain. 2012;28(9):775–781.
   Google Scholar
• Arnold LM, Arsenault P, Huffman C, et al. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin. 2014;30(10):2069–2083.
   Google Scholar
• Chappell AS, Bradley LA, Wiltse C, et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008;1:91–102.
   Google Scholar
• Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601–609.
   Google Scholar
• Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35(3):502–514.
   Google Scholar
• Murakami M, Osada K, Mizuno H, et al. A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Res Ther. 2015;17(1):224.
   Google Scholar
• Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011;38(12):2643–2652.
   Google Scholar
• Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432–444.
   Google Scholar
• Shakiba M, Moazen-Zadeh E, Ali Noorbala A, et al. Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial. Avicenna J Phytomed. 2018;8(6):513–523.
   Google Scholar
• Arnold LM, Clauw D, Wang F, et al. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2010;37(12):2578–2586.
   Google Scholar
• Mease PJ, Farmer MV, Palmer RH, et al. Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Ther Adv Musculoskelet Dis. 2013;5(3):113–126.
   Google Scholar
• Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336–1344.
   Google Scholar
• Arnold LM, Sarzi-Puttini P, Arsenault P, et al. Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo-controlled study. J Rheumatol. 2015;42(7):1237–1244.
   Google Scholar
• Arnold LM, Schikler KN, Bateman L, et al. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016;14(1):46.
   Google Scholar
• Bennett R, Clark S, Walczyk J. A randomized, c, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998;104(3):227–231.
   Google Scholar
• Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419–431.
   Google Scholar
• Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol. 2001;19(6):697–702.
   Google Scholar
• Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39(11):1852–1859.
   Google Scholar
• Mohs R, Mease P, Arnold LM, et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosom Med. 2012;74(6):628–634.
   Google Scholar
• Nasser K, Kivitz AJ, Maricic MJ, et al. Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken). 2014;66(2):293–300.
   Google Scholar
• Natelson BH, Vu D, Mao X, et al. Effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Pain. 2015;16(11):1211–1219.
   Google Scholar
• Ohta H, Oka H, Usui C, et al. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012;14(5):R217.
   Google Scholar
• Roth T, Lankford DA, Bhadra P, et al. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken). 2012;64(4):597–606.
   Google Scholar
• Upadhyaya HP, Arnold LM, Alaka K, et al. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J. 2019;17(1):27.
   Google Scholar
• Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23(5):255–259.
   Google Scholar
• Lawson K. Potential drug therapies for the treatment of fibromyalgia. Expert Opin Investig Drugs. 2016;25(9):1071–1081.
   Google Scholar
• Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 2010;35(6):639–656.
   Google Scholar
• Lawson K. Emerging pharmacological strategies for the treatment of fibromyalgia. World J Pharmacol. 2017;6(1):1–10.
   Google Scholar
• Boomershine CS. Pregabalin for the management of fibromyalgia syndrome. J Pain Res. 2010;3:81–88.
   Google Scholar
• Straube S, Derry S, Moore RA, et al. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford). 2010;49(4):706–715.
   Google Scholar
• Cooper TE, Derry S, Wiffen PJ, et al. Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev. 2017;1:CD012188.
   Google Scholar
• Welsch P, Uceyler N, Klose P, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2:CD010292.
   Google Scholar
• Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11(6):505–521.
   Google Scholar
• Lee YH, Song GG. Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int. 2016;36(5):663–672.
   Google Scholar
• Mathieson S, Lin CC, Underwood M, et al. Pregabalin and gabapentin for pain. BMJ. 2020;369:m1315.
   Google Scholar
• Wepner F, Scheuer R, Schuetz-Wieser B, et al. Effects of vitamin D on patients with fibromyalgia syndrome: a randomized placebo-controlled trial. Pain. 2014;155(2):261–268.
   Google Scholar
• Vergne-Salle P, Dufauret-Lombard C, Bonnet C, et al. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur J Pain. 2011;15(5):509–514.
   Google Scholar
• Posner I. Treatment of fibromyalgia syndrome with intravenous lidocaine: a prospective, randomized pilot study. J Musculoskelet Pain. 1994;2(4):55–65.
   Google Scholar
• Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61(3):445–449.
   Google Scholar
• Noppers I, Niesters M, Swartjes M, et al. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. Eur J Pain. 2011;15(9):942–949.
   Google Scholar
• Fiz J, Duran M, Capella D, et al. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One. 2011;6(4):e18440.
   Google Scholar
• Sagy I, Bar-Lev Schleider L, Abu-Shakra M, et al. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8(6). DOI:https://doi.org/10.3390/jcm8060807
   Google Scholar